Drugs / ipratropium/salbutamol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02576626 | Dec 2015 → Sep 2017 | chronic obstructive pulmonary disease | Wouter H. van Geffen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ipratropium/salbutamol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02576626 ↗ |
| Route | Inhaled | “ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation” NCT02576626 ↗ |